Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs).
GLP-1 weight-loss medications cause some muscle loss proportional to overall weight loss, but this shouldn't discourage their use when combined with exercise and good nutrition.
Meta-analysis of 7 RCTs (n=821) shows GLP-1 receptor agonists at obesity doses improve the lean/total weight ratio (+1.81%) despite absolute lean mass reduction (-1.74 kg on average; semaglutide -5.44 kg), with the largest effect from semaglutide. The findings clarify that the absolute lean mass loss is proportional to weight loss and should not contraindicate GLP-1 RA use when paired with nutritional and exercise support.
What the study was
- Study design
- Systematic review and meta-analysis of RCTs
- Population
- Adults with obesity treated with GLP-1 RA at obesity management doses
- Sample size
- 821
- Category
- Prevention
- Maturity
- Validated
- Journal
- International Journal of Obesity
Why it surfaced
Clinically relevant meta-analysis addressing a major concern (muscle loss) with GLP-1 RA in obesity; based on 7 RCTs. Moderate novelty but directly informs clinical practice guidance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.